drugset / Trial / NCT06621563
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid tumors.
Timeline
- Start
- 2024-12-14
- Primary completion
- 2026-03-30
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | HS-20093 | Other / unclassified | — | — |
| Subject | HS-20117 | Monoclonal antibody | — | — |
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Leucovorin | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | Pemetrexed | Small molecule | — | — |
| Subject | fluorouracil | Small molecule | — | — |